# Xingsheng Hu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/xingsheng-hu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,838 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 23 |
| i10-index | 50 |
| Last Known Institution | Capital Medical University |
| OpenAlex ID | https://openalex.org/A5045176687 |
| ORCID iD | 0000-0002-6652-2384 |
| Works | 164 |

## Researcher papers

- [Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study](https://scholariq.org/papers/efficacy-safety-and-genetic-analysis-of-furmonertinib-ast2818-in-patients-with/)
- [Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation](https://scholariq.org/papers/safety-clinical-activity-and-pharmacokinetics-of-alflutinib-ast2818-in-patients/)
- [Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer](https://scholariq.org/papers/evidence-of-ntrk1-fusion-as-resistance-mechanism-to-egfr-tki-in-egfr-nsclc/)
- [Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study](https://scholariq.org/papers/befotertinib-d-0316-versus-icotinib-as-first-line-therapy-for-patients-with-egfr/)
- [Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer](https://scholariq.org/papers/development-and-validation-of-a-radiomics-based-nomogram-for-predicting-a-major/)
- [Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes](https://scholariq.org/papers/acquired-resistance-to-osimertinib-in-patients-with-non-small-cell-lung-cancer/)
- [A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)](https://scholariq.org/papers/a-single-arm-multicenter-safety-monitoring-phase-iv-study-of-icotinib-in/)
- [Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients](https://scholariq.org/papers/clinical-significance-of-pretreatment-plasma-biomarkers-in-advanced-non-small/)
- [Diagnostic accuracy of transient elastography (FibroScan) in detection of esophageal varices in patients with cirrhosis: A meta-analysis](https://scholariq.org/papers/diagnostic-accuracy-of-transient-elastography-fibroscan-in-detection-of/)
- [Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China](https://scholariq.org/papers/clinical-characteristics-and-risk-factors-for-severity-of-covid-19-outside-wuhan/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Capital Medical University](https://scholariq.org/institutions/capital-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.